Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.

肝细胞癌 医学 内科学 脂肪肝 危险系数 荟萃分析 胃肠病学 优势比 肿瘤科
作者
Darren Jun Hao Tan,Cheng Han Ng,Snow Yunni Lin,Xin Hui Pan,Phoebe Tay,Wen Hui Lim,Margaret Teng,Nicholas Syn,Grace Lim,Jie Ning Yong,Jingxuan Quek,Jieling Xiao,Yock Young Dan,Mohammad Shadab Siddiqui,Arun J Sanyal,Mark D Muthiah,Rohit Loomba,Daniel Q Huang
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:23 (4): 521-530
标识
DOI:10.1016/s1470-2045(22)00078-x
摘要

The clinical presentation and outcomes of non-alcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma are unclear when compared with hepatocellular carcinoma due to other causes. We aimed to establish the prevalence, clinical features, surveillance rates, treatment allocation, and outcomes of NAFLD-related hepatocellular carcinoma.In this systematic review and meta-analysis, we searched MEDLINE and Embase from inception until Jan 17, 2022, for articles in English that compared clinical features, and outcomes of NAFLD-related hepatocellular carcinoma versus hepatocellular carcinoma due to other causes. We included cross-sectional and longitudinal observational studies and excluded paediatric studies. Study-level data were extracted from the published reports. The primary outcomes were (1) the proportion of hepatocellular carcinoma secondary to NAFLD, (2) comparison of patient and tumour characteristics of NAFLD-related hepatocellular carcinoma versus other causes, and (3) comparison of surveillance, treatment allocation, and overall and disease-free survival outcomes of NAFLD-related versus non-NAFLD-related hepatocellular carcinoma. We analysed proportional data using a generalised linear mixed model. Pairwise meta-analysis was done to obtain odds ratio (OR) or mean difference, comparing NAFLD-related with non-NAFLD-related hepatocellular carcinoma. We evaluated survival outcomes using pooled analysis of hazard ratios.Of 3631 records identified, 61 studies (done between January, 1980, and May, 2021; 94 636 patients) met inclusion criteria. Overall, the proportion of hepatocellular carcinoma cases secondary to NAFLD was 15·1% (95% CI 11·9-18·9). Patients with NAFLD-related hepatocellular carcinoma were older (p<0·0001), had higher BMI (p<0·0001), and were more likely to present with metabolic comorbidities (diabetes [p<0·0001], hypertension [p<0·0001], and hyperlipidaemia [p<0·0001]) or cardiovascular disease at presentation (p=0·0055) than patients with hepatocellular carcinoma due to other causes. They were also more likely to be non-cirrhotic (38·5%, 27·9-50·2 vs 14·6%, 8·7-23·4 for hepatocellular carcinoma due to other causes; p<0·0001). Patients with NAFLD-related hepatocellular carcinoma had larger tumour diameters (p=0·0087), were more likely to have uninodular lesions (p=0·0003), and had similar odds of Barcelona Clinic Liver Cancer stages, TNM stages, alpha fetoprotein concentration, and Eastern Cooperative Oncology Group (ECOG) performance status to patients with non-NAFLD-related hepatocellular carcinoma. A lower proportion of patients with NAFLD-related hepatocellular carcinoma underwent surveillance (32·8%, 12·0-63·7) than did patients with hepatocellular carcinoma due to other causes (55·7%, 24·0-83·3; p<0·0001). There were no significant differences in treatment allocation (curative therapy, palliative therapy, and best supportive care) between patients with NAFLD-related hepatocellular carcinoma and those with hepatocellular carcinoma due to other causes. Overall survival did not differ between the two groups (hazard ratio 1·05, 95% CI 0·92-1·20, p=0·43), but disease-free survival was longer for patients with NAFLD-related hepatocellular carcinoma (0·79, 0·63-0·99; p=0·044). There was substantial heterogeneity in most analyses (I2>75%), and all articles had low-to-moderate risk of bias.NAFLD-related hepatocellular carcinoma is associated with a higher proportion of patients without cirrhosis and lower surveillance rates than hepatocellular carcinoma due to other causes. Surveillance strategies should be developed for patients with NAFLD without cirrhosis who are at high risk of developing hepatocellular carcinoma.None.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
老大蒂亚戈应助潇湘雪月采纳,获得10
1秒前
1秒前
3秒前
3秒前
kk完成签到,获得积分10
3秒前
4秒前
HOPE发布了新的文献求助10
4秒前
AAA完成签到,获得积分10
6秒前
Singularity应助讨厌科研采纳,获得10
6秒前
古月发布了新的文献求助10
7秒前
8秒前
33发布了新的文献求助10
8秒前
汉堡包应助于平川春野采纳,获得10
8秒前
星星发布了新的文献求助10
10秒前
11秒前
赘婿应助十九岁的时差采纳,获得10
11秒前
怠惰vs勤劳完成签到,获得积分10
12秒前
夏天应助青山采纳,获得100
13秒前
14秒前
乖猫要努力应助潇湘雪月采纳,获得10
15秒前
wdy111举报风之星求助涉嫌违规
15秒前
古月完成签到,获得积分10
16秒前
16秒前
17秒前
吴所谓发布了新的文献求助50
20秒前
英吉利25发布了新的文献求助10
21秒前
22秒前
酷波er应助南冥采纳,获得10
22秒前
李沐唅完成签到 ,获得积分10
26秒前
lv完成签到,获得积分10
26秒前
周婷完成签到 ,获得积分10
27秒前
shy完成签到,获得积分10
27秒前
29秒前
犹豫的忆枫完成签到,获得积分10
29秒前
30秒前
夕沫发布了新的文献求助50
30秒前
勤奋大地发布了新的文献求助10
31秒前
乖猫要努力应助潇湘雪月采纳,获得10
31秒前
咚咚咚发布了新的文献求助30
33秒前
36秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989390
求助须知:如何正确求助?哪些是违规求助? 3531487
关于积分的说明 11254109
捐赠科研通 3270153
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809174